Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro.
OBJECTIVE
The aim of this study was to determine whether receptor-dependent and receptor-independent retinoids sensitize cervical cancer cells to clinically relevant doses of concurrent radiation and cisplatin.


METHODS
The clonogenic assay was performed on SiHa cervical carcinoma cultures treated with 5 microM 9-cis-retinoic acid (RA) or 3 microM 4-HPR for 3 days prior to and following concurrent treatment with 3 microM cisplatin and 2 Gy of Co(60) radiation.


RESULTS
Neither 9-cis-RA nor 4-HPR significantly decreased survival for radiation only or cisplatin only (t test: P < 0.05), but both significantly decreased survival of cultures receiving concurrent chemoradiation (t test: 9-cis-RA P = 0.045; 4-HPR P = 0.027).


CONCLUSIONS
Both receptor-dependent and receptor-independent retinoids enhance concurrent chemoradiation effects in vitro.
Scribner
Dennis R
DR
Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA.
Benbrook
Doris M
DM
D000077556:Alitretinoin; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004357:Drug Synergism; D005260:Female; D017313:Fenretinide / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D018168:Receptors, Retinoic Acid / Q000502:physiology; D014212:Tretinoin / Q000008:administration & dosage / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D018168:Receptors, Retinoic Acid; D017313:Fenretinide; D000077556:Alitretinoin; D014212:Tretinoin; D002945:Cisplatin